WGRX · Wellgistics Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.56M | - | $3.01M | $44.5K | $10.86M | - | - | - |
| Cost of Revenue | $1.39M | - | $2.78M | $47.1K | $10.17M | - | - | - |
| Gross Profit | $170.2K | - | $521.2K | ($2.6K) | $692.6K | - | - | - |
| R&D | - | - | - | - | - | - | - | - |
| SG&A | $4.87M | - | $1.80M | $570.4K | $79.8K | - | - | - |
| Total Operating Expenses | $6.19M | - | $31.78M | $570.4K | $79.8K | - | - | - |
| D&A | $356.8K | - | $467.4K | $802.8K | $802.9K | - | - | - |
| Operating Income | ($6.02M) | - | ($1.74M) | ($573.0K) | ($79.8K) | - | - | - |
| Interest Expense | $2.07M | - | $1.43M | $1.18M | $3.4K | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | ($7.74M) | - | ($34.32M) | ($574.3K) | ($83.1K) | - | - | - |
| EPS - Basic | ($0.07) | - | ($0.04) | ($0.11) | $0.00 | - | - | - |
| EPS - Diluted | ($0.07) | - | ($0.46) | ($0.01) | $0.00 | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $51.7K | $42.6K | $4.23M | $419.9K | $2.52M | $1.03M | $1.4K | - |
| Accounts Receivable | $992.1K | - | - | - | - | - | - | - |
| Inventory | $1.71M | $1.64M | $7.49M | $9.03M | $9.73M | $9.52M | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - |
| Current Assets | $2.76M | $2.82M | $12.82M | $13.51M | $16.55M | $15.17M | $338.4K | - |
| Total Assets | $30.13M | $30.46M | $52.78M | $54.23M | $58.06M | $57.33M | $338.4K | - |
| Current Liabilities | $32.20M | $29.78M | $32.74M | $42.40M | $46.23M | $38.05M | $2.89M | - |
| Long-term Debt | $12.60M | $12.60M | $12.60M | $11.46M | $24.12M | $23.38M | - | - |
| Total Liabilities | $45.19M | $42.91M | $46.00M | $53.32M | $53.58M | $50.60M | $3.24M | - |
| Stockholders' Equity | ($15.06M) | ($12.45M) | $6.78M | ($3.15M) | $4.48M | $6.73M | ($2.90M) | ($5.3K) |
| Retained Earnings | ($118.77M) | ($111.03M) | ($83.18M) | ($48.86M) | ($42.19M) | ($9.76M) | ($2.90M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.41M) | - | - | - | $31.2K | - | - | - |
| Investing Cash Flow | ($205.1K) | - | - | - | ($273.1K) | - | - | - |
| Financing Cash Flow | $3.63M | - | - | - | $260.0K | - | - | - |
| CapEx | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | 10.9% | - | 17.3% | -5.9% | 6.4% | - | - | - |
| Operating margin | -385.7% | - | -57.9% | -1286.5% | -0.7% | - | - | - |
| EBITDA margin | -362.8% | - | -42.4% | 515.9% | 6.7% | - | - | - |
| Net margin | -496.5% | - | -1139.0% | -1289.5% | -0.8% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 312.2% | - | 59.7% | 1280.7% | 0.7% | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -25.7% | - | -65.0% | -1.1% | -0.1% | - | - | - |
| Return on equity | 51.4% | - | -506.3% | 18.2% | -1.9% | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 0.09 | 0.09 | 0.39 | 0.32 | 0.36 | 0.40 | 0.12 | - |
| Quick ratio | 0.03 | 0.04 | 0.16 | 0.11 | 0.15 | 0.15 | 0.12 | - |
| Cash ratio | 0.00 | 0.00 | 0.13 | 0.01 | 0.05 | 0.03 | 0.00 | - |
| Leverage | ||||||||
| Debt / Equity | -0.84 | -1.01 | 1.86 | -3.64 | 5.39 | 3.47 | - | - |
| Debt / Assets | 0.42 | 0.41 | 0.24 | 0.21 | 0.42 | 0.41 | - | - |
| Debt / EBITDA | - | - | - | 49.85 | 33.36 | - | - | - |
| Interest coverage | -2.9x | - | -1.2x | -0.5x | -23.8x | - | - | - |
| Equity multiplier | -2.00 | -2.45 | 7.79 | -17.23 | 12.96 | 8.51 | -0.12 | - |
| Liabilities / Assets | 1.50 | 1.41 | 0.87 | 0.98 | 0.92 | 0.88 | 9.57 | - |
| Efficiency | ||||||||
| Asset turnover | 0.05 | - | 0.06 | 0.00 | 0.19 | - | - | - |
| Inventory turnover | 0.81 | - | 0.37 | 0.01 | 1.04 | - | - | - |
| Days sales outstanding | 232d | - | - | - | - | - | - | - |
| Days inventory outstanding | 450d | - | 983d | 69915d | 349d | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | -85.6% | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -75.4% | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -7441.7% | - | - | - | - | - | - | - |
| Net income growth (YoY) | -9214.7% | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | - | -55146.4% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$23.34M totalProduct$21.87M · 93.7%
Pharmacy Retail Sales$865.7K · 3.7%
Third Party Logistics Services$603.4K · 2.6%
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing Wellgistics Health against the 5 most active filers in the same SIC group.